Soohee Cho

Soohee Cho

Auto-generated profile, based on publicly available information

Soohee Cho

Division of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in Blood Advances
Verified
Journal Article
Open access
CDChristopher C. Dvorak
Christopher C. Dvorak
JLJanel R. Long-Boyle
Janel R. Long-Boyle
LHLucia Holbrook-Brown
Lucia Holbrook-Brown
HAHisham Abdel-Azim
Hisham Abdel-Azim
ABAlice Bertaina
Alice Bertaina
MPMichael A. Pulsipher
Michael A. Pulsipher
We hypothesized that the inferior disease-free survival (DFS) seen in older patients who underwent αβ-T-cell/CD19–depleted (AB-TCD) haploidentical hematopoietic cell transplantation (HCT) for hematologic malignancies is caused by excessive exposure to rabbit antithymocyte globulin (rATG; Thymoglobulin). Between 2015 and 2023, 163 patients with a median age of 13 years (range, 0.4-27.4) underwent AB-TCD haploidentical HCT for the treatment of acute lymphoblastic leukemia (n = 98), acute myeloid leukemia/myelodysplastic syndrome (n = 49), or other malignancies (n = 16) at 9 centers in 2 prospective trials. Exposures to rATG before and after HCT were predicted using a validated pharmacokinetic model. Receiver operating characteristic curves were used to identify the optimal target windows for rATG exposure in terms of outcomes. We identified 4 quadrants of rATG exposure, namely quadrant 1 (n = 52) with a high pre-HCT area under curve (AUC; ≥50 arbitrary units [AU] per day per milliliter) and a low post-HCT AUC (<12 AU per day per liter); quadrant 2 (n = 47) with a low pre- and post-HCT AUC; quadrant 3 (n = 13) with a low pre-HCT and a high post-HCT AUC; and quadrant 4 (n = 51) with a high pre- and post-HCT AUC. Quadrant 1 had a 3-year DFS of 86.5%, quadrant 2 had a DFS of 64.6%, quadrant 3 had a DFS of 32.9%, and for quadrant 4 it was 48.2%. An adjusted regression analysis demonstrated additional factors that were associated with an increased hazard for worse DFS, namely minimal residual disease (MRD) positivity and cytomegalovirus (CMV) R+/D− serostatus. Nonoptimal rATG exposure exhibited the strongest effect in unadjusted and adjusted (MRD status or CMV serostatus) analyses. High exposure to rATG after HCT was associated with inferior DFS following AB-TCD haploidentical HCT for pediatric patients with hematologic malignancies. Model-based dosing of rATG to achieve optimal exposure may improve DFS. These trials were registered at www.ClinicalTrials.gov as #NCT02646839 and #NCT04337515.

4 April 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CDChristopher C. Dvorak
Christopher C. Dvorak
SCSoohee Cho
Soohee Cho
GCGabriel Salinas Cisneros
Gabriel Salinas Cisneros
CHChristine S. Higham
Christine S. Higham
JCJulia Chu
Julia Chu
JLJanel R. Long-Boyle
Janel R. Long-Boyle
Melphalan is often used as the backbone agent for conditioning prior to A/B-T-cell depleted (A/B-TCD) hematopoietic cell transplant (HCT) due to lower rates of organ toxicity compared to busulfan or total-body irradiation, albeit with significant mucosal injury. Traditional dosing based on body-surface-area (BSA) may result in non-optimal melphalan exposure among certain patient subsets. As mucosal injury is linked to initiation of alloreactivity, we hypothesized that high exposure of melphalan predicted via a pharmacokinetic (PK) model would be associated with an increased risk of acute graft-versus-host disease (aGVHD). We performed an analysis of 85 patients who underwent A/B-TCD haploidentical HCT on two prospective trials using melphalan-based conditioning for treatment of malignancy at three centers from 2015-2024. Most patients (61.2%) received a total dose of melphalan at 140 mg/m2 using actual body weight; others received a dose adjusted for obesity or age <2 years. We analyzed outcomes based on whether melphalan exposure was above or below the median exposure for the group. The 100-day cumulative incidences of engraftment syndrome (ES), grade II-IV aGVHD, and grade III-IV aGVHD were 34.2%, 24.8%, and 17.1%, respectively. The 3-year cumulative incidence of chronic GVHD (cGVHD), non-relapse mortality (NRM), and relapse were 17.5%, 8.7%, 21.8%, respectively. The 3-year cumulative incidence of disease-free survival (DFS) and severe GVHD-relapse-free survival (GRFS) were 71.4% and 55.6%, respectively. ES was significantly associated with the subsequent development of aGVHD, both grade II-IV (41.4% vs. 17.3% in those with and without ES, p=0.01) and grade III-IV (34.5% vs. 8.5% in those with and without ES; p=0.003). Chronic GVHD occurred at significantly higher rates in patients with prior Grade II-IV (66.7% vs. 0% for Grade 0-I; p<0.001) and Grade III-IV aGVHD (75% vs. 4.3% for Grade 0-II; p6.8 mg*hr/L was associated with a higher incidence of ES (48.8% vs. 19.1%; p=0.005), grade II-IV aGVHD (39.3% vs. 10.1%; p=0.002), and grade III-IV aGVHD (31.5% vs. 2.5%; p<0.001). The 3-year incidence of cGVHD was 27.2% in those with high predicted melphalan exposure compared to 7.4% for low exposure (p=0.03); with no difference in 3-year NRM incidence (9.2% vs. 7.7%; p=0.82) or 3-year relapse incidence (16.8% vs. 27.6%; p=0.31) for high compared to low exposure. However, GRFS was significantly worse in patients with high exposure (46.4%) vs. low exposure (64.6%; p=0.02). High melphalan exposure predicted by a validated population PK model is associated with an increased likelihood of developing ES and subsequently acute and chronic GVHD. Given that a substantial number of patients already require adjustment of standard BSA-based dosing for young age or obesity, a prospective trial of model-based dosing to individualize melphalan exposure is warranted to confirm these results.

27 March 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
ARAhmad Rayes
Ahmad Rayes
ARAkshaya Ramachandran
Akshaya Ramachandran
MPMichael A. Pulsipher
Michael A. Pulsipher
JDJ. Gregory Dolan
J. Gregory Dolan
SCSoohee Cho
Soohee Cho
RBRosa Bacchetta
Rosa Bacchetta
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a life-threatening monogenic inborn error of immunity caused by pathogenic variants in the FOXP3 gene. In this report, we describe the clinical and immunologic consequences of a novel FOXP3 variant in an infant with refractory IPEX syndrome. Rapid whole-genome sequencing revealed a missense variant c.1050C>G (p.Ile350Met) in the forkhead domain of FOXP3. FOXP3 expression was abrogated in the regulatory T cell (Treg) subset but was maintained at low levels in activated effector T cells. The frequency of Treg-specific demethylated region (TSDR)–demethylated T cells was within normal range at birth, but it increased to pathologically high levels at 2 wk of age, prior to manifestation of disease symptoms. These results support the clinical relevance of the TSDR-demethylated cell percentage in evaluation of disease activity in IPEX. This case highlights a severe form of IPEX syndrome refractory to multiple immunosuppressive agents and the importance of early immunological studies to verify the clinical significance of novel genetic findings.

27 January 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
SCSoohee Cho
Soohee Cho
TVTim Vigers
Tim Vigers
LPLaura Pyle
Laura Pyle
AFAnna Franklin
Anna Franklin
JSJenna Sopfe
Jenna Sopfe
GFGregory Forlenza
Gregory Forlenza
Background: Malglycemia in pediatric, adolescent and young adult (AYA) patients who undergo hematopoietic stem cell transplant (HSCT) is associated with increased infection and mortality rate. Continuous glucose monitoring (CGM) has been safely used in pediatric/AYA HSCT recipients, but there is a need for a composite metric that can easily be used in clinical settings to assess the glycemic control and identify high-risk patients who needs therapeutic intervention. Composite metrics derived from CGM have not been studied in pediatric/AYA HSCT patients. Methods: Patients aged 2–30 years old who are admitted inpatient while undergoing HSCT at Children's Hospital Colorado underwent CGM using the Abbot Freestyle Libre Pro device from up to 7 days before and 60 days after HSCT. A composite metric Q -score, comprising five primary factors of CGM profiles (central tendency, hyperglycemia, hypoglycemia, intradaily variations, and interdaily variations), was calculated for each patient for the duration of CGM wear. Results: Twenty-nine patients received CGM for an average of 25 days per participant. The median Q -score was 10.2 (interquartile range [IQR]: 8.3, 14.3). Sixty-nine percent of patients had Q -scores that would be categorized into the Fair or Poor category. There was no difference in the Q -score by sources of stem cell, types of primary disease, types of preparative regimen, need for PICU admission, presence of documented infections, and total parenteral nutrition use in the peri-HSCT period. Conclusions: Most pediatric/AYA HSCT recipients have Q -scores indicating suboptimal glycemic control in the peri-HSCT period. Future study should focus on developing screening and treatment strategies to improve malglycemia and its associated adverse clinical outcomes. This study was registered at clinicaltrials.gov (NCT03482154).

19 August 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CDChristopher C. Dvorak
Christopher C. Dvorak
WCWillem Collier
Willem Collier
SCSoohee Cho
Soohee Cho
LHLucia Holbrook-Brown
Lucia Holbrook-Brown
CRCandelaria Deimundo Roura
Candelaria Deimundo Roura
JLJanel R. Long-Boyle
Janel R. Long-Boyle